









Markets
/
Stocks
/
nasdaq-snn
/

Smith & Nephew PLC

SNN

34.690USD

-0.480-1.36%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

15.19BMarket Cap

30.87P/E TTM



Smith & Nephew PLC

34.690

-0.480-1.36%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Smith & Nephew PLC

Currency: USD Updated: 2026-02-06

Key Insights

Smith & Nephew PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered undervalued, ranking 69 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 33.83.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Smith & Nephew PLC's Score

Industry at a Glance

Industry Ranking

69 / 205

Overall Ranking

182 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Smith & Nephew PLC Highlights

StrengthsRisks

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 5.81B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 79.37%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 79.37%.

Undervalued

The company’s latest PE is 30.87, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 32.25M shares, decreasing 24.19% quarter-over-quarter.

Held by Ray Dalio

Star Investor Ray Dalio holds 203.99K shares of this stock.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

33.833

Target Price

-3.80%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Smith & Nephew PLC is 8.87, ranking 26 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.87

Change



Financials

6.36

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

8.01

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Smith & Nephew PLC's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Smith & Nephew PLC is 3.98, ranking 197 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 30.87, which is 46.46% below the recent high of 45.21 and 15.45% above the recent low of 26.10.

Score

Industry at a Glance

Previous score

3.98

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 69/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Smith & Nephew PLC is 7.00, ranking 146 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 35.75, with a high of 39.00 and a low of 26.13.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

33.833

Target Price

-3.80%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

Smith & Nephew PLC

SNN

Stryker Corp

SYK

Abbott Laboratories

ABT

Medtronic PLC

MDT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Smith & Nephew PLC is 8.87, ranking 26 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 36.06 and the support level at 32.60, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.13

Change

-0.26

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.349

Buy

RSI(14)

59.687

Neutral

STOCH(KDJ)(9,3,3)

78.718

Neutral

ATR(14)

0.638

High Vlolatility

CCI(14)

76.893

Neutral

Williams %R

20.183

Buy

TRIX(12,20)

0.176

Sell

StochRSI(14)

20.315

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

34.678

Buy

MA10

34.290

Buy

MA20

33.595

Buy

MA50

33.262

Buy

MA100

34.305

Buy

MA200

32.975

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Smith & Nephew PLC is 3.00, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 7.59%, representing a quarter-over-quarter decrease of 1.69%. The largest institutional shareholder is Brandes Investmen, holding a total of 1.25M shares, representing 0.29% of shares outstanding, with 16.37% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BMO Capital Markets (US)

3.23M

+1.23%

River Road Asset Management, LLC

2.78M

-12.43%

Scharf Investments, LLC

2.03M

-2.61%

Brandes Investment Partners, L.P.

Star Investors

1.25M

-22.08%

Optiver Holding B.V.

1.10M

-4.43%

Goldman Sachs Asset Management, L.P.

1.09M

+1.46%

Parametric Portfolio Associates LLC

1.02M

+4.51%

BNP Paribas Securities Corp. North America

937.94K

+45.52%

BofA Global Research (US)

862.28K

+250.03%

Morgan Stanley & Co. LLC

770.49K

-6.44%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Smith & Nephew PLC is 8.13, ranking 26 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.